Oxford BioDynamics Subsidiary Signs Exclusive Asia Licence for EpiSwitch™

BioDynamics Plc is pleased to announce that its subsidiary, Oxford BioDynamics Pte Ltd has signed an exclusive licence agreement with Nova Satra Diagnostics Asia Limited (NSDA), to supply its proprietary products and reagents for the potential use in a non-invasive blood test to assist in the diagnosis of breast cancer, in complementation to current breast cancer screening procedures, across 13 territories in Asia. Specifically for Malaysia, Oxford BioDynamics has granted its consent for NSDA to grant an exclusive sub-licence to Genting Laboratory Services Sdn Bhd, a wholly owned subsidiary of Genting Berhad, to provide the proprietary breast cancer test.

Under the terms of the agreement, the Licence exclusively grants NSDA the right to use Oxford BioDynamics’ proprietary products and reagents, provided through the Company’s EpiSwitch™technology platform, for breast cancer patients stratification. NSDA will be solely responsible for completing the regulatory approval process and commercialisation activities of the breast cancer test within 13 territories in Asia. In return, Oxford BioDynamics will receive an upfront licensing payment, royalties on sales of the test and fees on the achievement of certain material undisclosed milestones.

Christian Hoyer Millar, Chief Executive Officer of Oxford BioDynamics, said:

“Our proprietary EpiSwitch™ technology will be instrumental in the development of this novel blood-based test that will assist in the diagnosis of breast cancer in the Asian population.

“We are very pleased to be collaborating with Nova Satra Diagnostics and look forward to developing our relationship with the team further.”

Kane Black, Chief Executive Officer of Nova Satra Diagnostics Asia, commented: “We are pleased to be working with Oxford BioDynamics in Asia on this test, the first of a suite of innovative tests we are developing for patients specifically in Asia.”

Kong Han Tan, President and Chief Operating Officer of Genting Berhad, added: “We are excited to be granted exclusive distribution rights in Malaysia for the breast cancer test using Oxford BioDynamics’ proprietary EpiSwitch™ technology and we welcome the opportunity to work with Oxford BioDynamics for the transfer of their technology to our labs in Malaysia to enable us deliver a non-invasive blood test to assist in the diagnosis of breast cancer.”